Related Experiment Video
Updated: Mar 9, 2026
Methods for Evaluating the Role of c-Fos and Dusp1 in Oncogene Dependence
Published on: January 7, 2019
Emerging role of SETDB1 as a therapeutic target
Archana Venkataramana Karanth1, Radhika Radha Maniswami1, Seema Prashanth1
1a Bioinformatics, Jubilant Biosys Ltd. , Bangalore , India.
Introduction:
Epigenetic changes lead to aberrant gene expression in cancer. SETDB1, a histone lysine methyltransferase plays an important role in methylation and gene silencing. Aberrant histone methylation at H3K9 by SETDB1 promotes silencing of tumor suppressor genes and thus contributes to carcinogenesis. Recent studies indicate that SETDB1 is abnormally expressed in various human cancer conditions which contributed to enhanced tumor growth and metastasis. Hence, SETDB1 appears to be a promising epigenetic target for therapeutic intervention. Areas covered: In this article, the structural features, localization and functions of SETDB1 are reviewed. Also, an overview of the role of SETDB1 in cancer and other disease mechanisms, the currently studied inhibitors for SETDB1 are mentioned. Expert opinion: Silencing of tumor suppressor genes due to excessive trimethylation at H3K9 by amplified SETDB1 levels is found in various cancerous conditions. Since epigenetic changes are reversible, SETDB1 holds promise as an important therapeutic target for cancer. Therefore, a better understanding of the role of SETDB1 and its interaction with various proteins in cancer-related mechanisms along with therapeutic interventions specific for SETDB1 may improve targeted cancer therapy.
Insights
SETDB1, a key epigenetic regulator, silences tumor suppressor genes in cancer. Targeting SETDB1 offers a promising therapeutic strategy for reversing aberrant gene expression and treating various cancers.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Epigenetic modifications drive abnormal gene expression in cancer.
- SETDB1 (histone-lysine methyltransferase) mediates methylation and gene silencing.
- Aberrant H3K9 methylation by SETDB1 silences tumor suppressors, promoting carcinogenesis.
Purpose of the Study:
- To review the structural features, localization, and functions of SETDB1.
- To provide an overview of SETDB1's role in cancer and disease.
- To discuss current SETDB1 inhibitors and therapeutic potential.
Main Methods:
- Literature review of SETDB1's role in cancer.
- Analysis of structural and functional data.
- Overview of existing therapeutic strategies.
Main Results:
- SETDB1 is abnormally expressed in various cancers, enhancing tumor growth and metastasis.
- SETDB1-mediated H3K9 trimethylation silences tumor suppressor genes.
- SETDB1 is a promising epigenetic target for cancer therapy.
Conclusions:
- SETDB1's role in silencing tumor suppressors makes it a significant therapeutic target.
- Reversible epigenetic changes mediated by SETDB1 offer potential for targeted cancer therapy.
- Further understanding of SETDB1 interactions and targeted interventions can improve cancer treatment.
More Related Videos
09:46Analysis of Gene Expression Changes in the Rat Hippocampus After Deep Brain Stimulation of the Anterior Thalamic Nucleus
Published on: March 8, 2015
05:33High-Throughput Cellular Profiling of Targeted Protein Degradation Compounds Using HiBiT CRISPR Cell Lines
Published on: November 9, 2020
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Therapeutic Drug Monitoring: Affecting Factors